New Horizons in Severe Asthma

Program Overview 

Prepare to take part in a unique educational journey through a series of engaging activities that make up this Interactive Showcase™ in severe asthma (SA). The first activity, designed as an expert-guided, virtual poster tour, will briefly review the underlying mechanisms of SA. Next, you will view an expert roundtable discussion where faculty discuss evolving management approaches, including the use of newer agents that target inflammatory mediators of disease. During the final activity, you will participate in two interactive case studies, applying information acquired to real-time management decisions. 

Target Audience 

The educational design of this activity addresses the needs of clinical immunologists/allergists, pulmonologists, and other specialist clinicians involved in the treatment of patients with SA. 

Educational Objectives  

After completing this activity, the participant should be better able to: 

• Describe key pathophysiologic processes in severe asthma development and persistence, including the roles of thymic stromal lymphopoietin (TSLP) and implications for treatment 
• Discuss the clinical profiles and recent trial results with newer biologic therapies for severe asthma 
• Construct biologic-based treatment regimens for patients with severe asthma to maximize asthma control, prevent exacerbations, and incorporate shared clinical decision making 

Physician Accreditation Statement 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications.  Global is accredited by the ACCME to provide continuing medical education for physicians. 

Physician Credit Designation 

Global designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Nurse Practitioner Continuing Education 

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.0 contact hour(s) (which includes 0.2 hour(s) of pharmacology). 

Global Contact Information 

For information about the approval of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com. 

Instructions to Receive Credit 

In order to receive credit for this activity, the participant must score at least 75% on the posttest and complete the program evaluation.  

Fee Information& Refund/Cancellation Policy 

There is no fee for this educational activity. 

Disclosures of Relevant Financial Relationships

Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global.  All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.   

All relevant financial relationships have been mitigated.  

The faculty have the following relevant financial relationships with ineligible companies: 

Monica Kraft, MD: Consulting Fee: AstraZeneca plc, Chiesi USA, Inc., Sanofi S.A.; Contracted Research: AstraZeneca plc, Sanofi S.A.; Honoraria: Chiesi USA, Inc. 

Erika Gonzalez, MD: Contracted Research: AstraZeneca plc, Genentech, Inc., Novartis Pharmaceuticals Corporation, Teva Pharmaceutical Industries Ltd. 

Jonathan Corren, MD: Consulting Fee: AstraZeneca plc, Regeneron Pharmaceuticals, Inc., Sanofi S.A.; Contracted Research: Amgen, Inc., AstraZeneca plc, Novartis Pharmaceuticals Corporation, Optinose US, Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd.; Speakers Bureau: Amgen, Inc., AstraZeneca plc, Regeneron Pharmaceuticals, Inc., Sanofi S.A. 

The planners and managers at Global Education Group and Integritas Communications have no relevant financial relationships to disclose. 

Disclosures of Unlabeled Use 

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer 

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.